DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC
Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain
Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC
Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma